A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

NCT00191490 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Gemcitabine
DRUG: docetaxel
DRUG: cisplatin

Sponsor

Eli Lilly and Company

Collaborators

[object Object]